{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:20:54Z","timestamp":1792264854438,"version":"4.4.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing Municipality","doi-asserted-by":"publisher","award":["NSFC"],"award-info":[{"award-number":["NSFC"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson's disease dementia (PDD) imposes a significant burden on patients and healthcare systems but currently lacks specific biomarkers. This study aimed to identify novel cerebrospinal fluid (CSF) biomarkers for PDD using proteomics and to explore their functional significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Employing iTRAQ-based quantitative proteomics, we analyzed CSF from 73 participants included 34 PD patients, 14 PDD patients and and 25 healthy Controls (HCs). Bioinformatics analysis identified 44 differentially expressed proteins in PDD compared to PD (33 upregulated, 11 downregulated). Subsequent validation by ELISA confirmed a significant decrease in Insulin-like Growth Factor Binding Protein 3 (IGFBP3) concentration in PDD CSF compared to PD, while other candidates (NXPH1, LRRN1, HPRT1) showed no significant differences.\n                      <jats:italic>In vitro<\/jats:italic>\n                      functional studies using SH-SY5Y neuroblastoma cells demonstrated that IGFBP3 significantly attenuated cytotoxicity and apoptosis induced by the neurotoxin MPP\n                      <jats:sup>+<\/jats:sup>\n                      . IGFBP3 pretreatment improved cell viability (assessed by CCK-8 assay), reduced lactate dehydrogenase (LDH) release, and decreased apoptosis rates (measured by flow cytometry). Mechanistically, IGFBP3 counteracted MPP\n                      <jats:sup>+<\/jats:sup>\n                      -induced dysregulation of apoptosis markers (increased Bcl-2\/Bax ratio; reduced cleaved caspase-3\/caspase-3 ratio) and activated the PI3K\/Akt\/GSK3\u03b2 signaling pathway by restoring phosphorylation levels of PI3K, Akt, and GSK3\u03b2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      These findings suggest that decreased CSF IGFBP3 is a potential biomarker for PDD. Furthermore, IGFBP3 exerts neuroprotective effects against MPP\n                      <jats:sup>+<\/jats:sup>\n                      toxicity, likely mediated through the activation of PI3K\/Akt\/GSK3\u03b2 pathway and inhibition of apoptosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      IGFBP3 warrants further investigation as a diagnostic biomarker and therapeutic target for PDD, necessitating future validation in larger cohorts and\n                      <jats:italic>in vivo<\/jats:italic>\n                      models.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnins.2025.1682274","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:23:21Z","timestamp":1762496601000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Revealing cerebrospinal fluid biomarkers in Parkinson's disease dementia based on iTRAQ proteomics research"],"prefix":"10.3389","volume":"19","author":[{"given":"Lin","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huahua","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guotao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhe","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiFen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.18502\/ijps.v19i4.16548","article-title":"Comparison of brain activity between patients with Parkinson disease dementia and patients affected by dementia with lewy body through EEG analysis","volume":"19","author":"Abbood","year":"2024","journal-title":"Iran J. Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1872214810999160628105549","article-title":"Parkinson's disease, diabetes and cognitive impairment","volume":"10","author":"Ashraghi","year":"2016","journal-title":"Recent Pat Endocr. Metab. Immune Drug Discov."},{"key":"B3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.ajpath.2016.10.011","article-title":"Insulin-like growth factor binding protein-3 deficiency leads to behavior impairment with monoaminergic and synaptic dysfunction","volume":"187","author":"Dai","year":"2017","journal-title":"Am. J. Pathol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.04.009","article-title":"Cognitive decline and quality of life in incident Parkinson's disease: the role of attention","volume":"27","author":"Lawson","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/1091581811423845","article-title":"Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax\/Bcl-2 ratio and caspase-9-dependent pathway","volume":"31","author":"Lee","year":"2012","journal-title":"Int. J. Toxicol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3892\/br.2013.153","article-title":"Effects of apoptosis-related proteins caspase-3, Bax and Bcl-2 on cerebral ischemia rats","volume":"1","author":"Liu","year":"2013","journal-title":"Biomed. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000371510","article-title":"Plasma insulin-like growth factor 1 is associated with cognitive impairment in Parkinson's disease","volume":"39","author":"Ma","year":"2015","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.1007\/s00415-022-11267-9","article-title":"Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease","volume":"269","author":"Nwabufo","year":"2022","journal-title":"J. Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(19)30024-9","article-title":"CSF and blood biomarkers for Parkinson's disease","volume":"18","author":"Parnetti","year":"2019","journal-title":"Lancet Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-1-0716-1024-4_8","article-title":"Quantitative mass spectrometry-based proteomics: an overview","volume":"2228","author":"Rozanova","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1210\/clinem\/dgab121","article-title":"Investigating the relationship between IGF-I, IGF-II, and IGFBP-3 concentrations and later-life cognition and brain volume","volume":"106","author":"Salzmann","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/10731911251339362","article-title":"Cognitive performance in Parkinson's spectrum disorders: a comparative study of patients with Parkinson's disease, Parkinson's disease dementia, dementia with lewy bodies, progressive supranuclear palsy, and corticobasal syndrome","author":"van Breugel","year":"2025","journal-title":"Assessment"},{"key":"B14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41419-019-1407-6","article-title":"BCL-2 family isoforms in apoptosis and cancer","volume":"10","author":"Warren","year":"2019","journal-title":"Cell Death Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1002\/pmic.201300361","article-title":"IQuant: an automated pipeline for quantitative proteomics based upon isobaric tags","volume":"14","author":"Wen","year":"2014","journal-title":"Proteomics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3390\/cells8111317","article-title":"Autophagic- and lysosomal-related biomarkers for parkinson's disease: lights and shadows","volume":"8","author":"Xicoy","year":"2019","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","first-page":"107953","DOI":"10.1016\/j.parkreldis.2025.107953","article-title":"Cognitive function, psychobehavioral symptoms, and MRI features in patients with non-demented Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies","volume":"138","author":"Xu","year":"2025","journal-title":"Parkinsonism Relat. Disord."},{"key":"B18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fnins.2018.00073","article-title":"The role of insulin\/IGF-1\/PI3K\/Akt\/GSK3\u03b2 signaling in Parkinson's disease dementia","volume":"12","author":"Yang","year":"2018","journal-title":"Front. Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1007\/s11064-017-2184-1","article-title":"Intranasal administration of gdnf protects against neural apoptosis in a rat model of parkinson's disease through PI3K\/Akt\/GSK3\u03b2 pathway","volume":"42","author":"Yue","year":"2017","journal-title":"Neurochem. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9450137","DOI":"10.1155\/2016\/9450137","article-title":"Neuroprotective effects of salidroside in the MPTP mouse model of Parkinson's disease: involvement of the PI3K\/Akt\/GSK3\u03b2 pathway","volume":"2016","author":"Zhang","year":"2016","journal-title":"Parkinsons Dis."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2025.1682274\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:23:22Z","timestamp":1762496602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2025.1682274\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":20,"alternative-id":["10.3389\/fnins.2025.1682274"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2025.1682274","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1682274"}}